RSS
AERI

Rosenblum Silverman Sutton’s Aerie Pharmaceuticals AERI Stock Holding History

Rosenblum Silverman Sutton’s Portfolio AERI Stock Details AERI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		$533K Buy
+21,900
New +$511K 0.24% 56
2014
Q4 		$356K Buy
+12,200
New +$309K 0.15% 68

Other funds holding AERI

Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
TGHSA
TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Rosenblum Silverman Sutton's AERI Position: Q4 2015 in Review

Rosenblum Silverman Sutton opened a new position in Aerie Pharmaceuticals (AERI) in Q4 2015: 21,900 shares worth $533K. The stake represents 0.24% of the portfolio and ranks #56 among its holdings. This is a return to the name: Rosenblum Silverman Sutton previously reported a position in AERI as recently as Q4 2014.

Rosenblum Silverman Sutton first reported a position in AERI in Q4 2014 and has held it in 2 quarters since. 116 funds tracked by Wall St. Rank hold AERI as of Q4 2015.

  • Rosenblum Silverman Sutton held 21,900 shares of Aerie Pharmaceuticals worth $533K as of Q4 2015.
  • Aerie Pharmaceuticals was a new Rosenblum Silverman Sutton position in Q4 2015.
  • Aerie Pharmaceuticals made up 0.24% of Rosenblum Silverman Sutton's portfolio in Q4 2015, its #56 holding.
  • Rosenblum Silverman Sutton first reported a position in Aerie Pharmaceuticals in Q4 2014 and has held it in 2 quarters since.
  • 116 funds tracked by Wall St. Rank held Aerie Pharmaceuticals as of Q4 2015.

Based on Rosenblum Silverman Sutton's 13F filing for Q4 2015, filed 16 Feb 2016.